¹⁷⁷Lu-PSMA radioligand therapy for metastatic castration-resistant prostate cancer.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Transliterated Title:
      Behandling av kastrasjonsresistent metastatisk prostatakreft med [¹⁷⁷Lu]PSMA-radioligand.
    • Source:
      Publisher: Norske Laegeforening Country of Publication: Norway NLM ID: 0413423 Publication Model: Electronic-Print Cited Medium: Internet ISSN: 0807-7096 (Electronic) Linking ISSN: 00292001 NLM ISO Abbreviation: Tidsskr Nor Laegeforen Subsets: MEDLINE
    • Publication Information:
      Publication: Oslo : Norske Laegeforening
      Original Publication: Chistiania : Alb. Cammermeyer, 1880-
    • Subject Terms:
      Prostatic Neoplasms, Castration-Resistant*/radiotherapy ; Prostatic Neoplasms, Castration-Resistant*/pathology ; Radiopharmaceuticals*/therapeutic use ; Radiopharmaceuticals*/pharmacokinetics ; Prostate-Specific Antigen*/blood ; Positron Emission Tomography Computed Tomography* ; Lutetium*/therapeutic use ; Gallium Radioisotopes*; Humans ; Male ; Aged ; Lymphatic Metastasis ; Dipeptides/therapeutic use ; Dipeptides/pharmacokinetics ; Oligopeptides ; Gallium Isotopes
    • Abstract:
      Background: Treatment of castration-resistant metastatic prostate cancer with [¹⁷⁷Lu]PSMA radioligand.
      Case Presentation: A man in his seventies with metastatic prostate cancer received castration therapy for four years, developing castration-resistant disease. PET/CT with [⁶⁸Ga]PSMA-11 showed high uptake in metastatic lymph nodes. The patient received 7.4 GBq [¹⁷⁷Lu]PSMA-I&T (Curium, Finland) as five treatments at five-week intervals. Five weeks after the first treatment, p-PSA dropped from 154 to 53 µg/L. Five weeks after the fifth treatment, p-PSA was 1.8 µg/L. [⁶⁸Ga]PSMA-11 PET/CT showed significant reduction in the size of metastases, with the largest decreasing in diameter from 10 to 4 mm. Seven months after the fifth treatment, p-PSA increased to 14.3 µg/L, and [⁶⁸Ga]PSMA-11 PET/ CT revealed additional skeletal metastases, while the lymph node metastases remained unchanged. Thus, the treatment had a good but temporary effect on the metastases.
      Interpretation: Treatment with [¹⁷⁷Lu]PSMA radioligand resulted in a temporary regression of the metastases.
    • Accession Number:
      0 (Radiopharmaceuticals)
      EC 3.4.21.77 (Prostate-Specific Antigen)
      5H0DOZ21UJ (Lutetium)
      0 (Gallium Radioisotopes)
      0 (Dipeptides)
      0 (gallium 68 PSMA-11)
      0 (Oligopeptides)
      0 (Gallium Isotopes)
    • Publication Date:
      Date Created: 20240821 Date Completed: 20240821 Latest Revision: 20240823
    • Publication Date:
      20240823
    • Accession Number:
      10.4045/tidsskr.23.0478
    • Accession Number:
      39166985